Surgical Resection Enhances Survival in Gastric-type Endocervical Adenocarcinoma: A SEER-Based Study

NCT07026825 | Completed

• 1 other identifier: JS2024-32-1
• Study Type: observational
• Target: 308
• Locations: 0 countries
• Sites: N/A

Brief Summary

This retrospective cohort study analyzes the effect of surgical resection on survival outcomes in patients with gastric-type endocervical adenocarcinoma (GAS), using data from the SEER database (2000-2021). Propensity score matching and multivariable Cox regression were used to compare overall survival (OS) and tumor-specific survival (TSS) between patients who underwent surgery and those who did not. The study aims to determine whether primary tumor resection is associated with improved survival across tumor sizes and stages.

Conditions

Gastric-type Endocervical Adenocarcinoma

Outcome Measures

Primary Outcomes (1)

• Outcome

  Overall Survival (OS)

  Time from diagnosis to death from any cause Up to 22 years (2000-2022)

Study Arms (2)

surgical Resection Group

Participants in this group undergo standard surgical resection aimed at the complete or partial removal of tumor tissue. The type of surgery-open or minimally invasive-is determined based on the patient's clinical condition and the surgeon's judgment. Preoperative and/or postoperative adjuvant therapies, such as chemotherapy or radiotherapy, may be administered to enhance treatment efficacy.

Non-Surgical Management Group

Participants in this group receive standard non-surgical treatments, including chemotherapy, radiotherapy, targeted therapy, or immunotherapy. The specific treatment regimen is tailored to the patient's condition and determined by the treating physician, aiming to control tumor progression, alleviate symptoms, and improve quality of life.

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This study enrolled patients aged 18 years and older with histologically confirmed gastric-type endocervical adenocarcinoma and no prior history of other malignancies.

You may qualify if:

• Histologically confirmed gastric-type endocervical adenocarcinoma Cervix as the first primary site Diagnosis between 2000 and 2021

You may not qualify if:

• Incomplete survival or treatment data Diagnosis not confirmed microscopically

Sponsors & Collaborators

• Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center: lead

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 10, 2025
• First Posted: June 18, 2025
• Study Start: January 1, 2000
• Primary Completion: December 30, 2021
• Study Completion: December 30, 2022
• Last Updated: June 18, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will not share